A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea

NCT06565871 | Not Yet Recruiting Phase 2

• 1 other identifier: HRS9531-206
• Study Type: interventional
• Target: 108
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to evaluate the effect and safety of HRS9531 Injection in Obese Subjects with Obstructive Sleep Apnea

Conditions

Weight Management

Outcome Measures

Primary Outcomes (1)

• Percentage change from baseline in body weight

  Baseline,32week

Secondary Outcomes (7)

• Change from Baseline in Apnea-Hypopnea Index (AHI)

  Baseline,32week

• Proportion of subjects with weight loss of ≥5% from baseline after 32 weeks of treatment

  Week 32

• Proportion of subjects with weight loss of ≥10% from baseline after 32 weeks of treatment

  Week 32

• Proportion of subjects with weight loss of ≥15%from baseline after 32 weeks of treatment

  Week 32

• Change from Baseline in Body weight

  Baseline,32week

Study Arms (3)

HRS9531 Injection low dose

EXPERIMENTAL

Drug: HRS9531 Injection

HRS9531 Injection high dose

EXPERIMENTAL

Drug: HRS9531 Injection

Placebo

PLACEBO COMPARATOR

Drug: Placebo Injection

Interventions

HRS9531 Injection DRUG

Titration administration, SC

HRS9531 Injection low dose

Placebo Injection DRUG

SC

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects, age 18-65(both inclusive) at the time of signing informed consent.
• At screening visit, BMI 24-42kg/m2(both inclusive)
• Self-reported Diet and exercise control for at least 3 months before screening visit, and less than 5 kg self-reported change within the last 3 months.
• At screening visit, AHI ≥15 and Obstructive Sleep Apnea on PSG

You may not qualify if:

• Endocrine disorders that may significantly affect body weight, or obesity or hereditary obesity syndrome due to a single gene mutation;
• Diabetes (except gestational diabetes)
• There are diseases that may require systemic glucocorticoid therapy during the study period
• Previous or known history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine adenomatosis type 2 (MEN2)
• In or suspected of depression, bipolar disorder, suicidal tendencies, schizophrenia or other more serious mental illness;
• Use of drugs or treatments that may lead to significant weight gain or loss within 3 months, use of stimulants and hypnotics, mirtazapine, opioids, trazodone within 3 months;
• Patients with a history of blood donation or blood loss ≥400 ml within 3 months prior to screening, or receiving blood transfusions within 3 months
• During the screening or before randomization ,laboratory examination meets the following conditions:
• Fasting blood glucose ≥7.0 mmol/L, or HbA1c ≥6.5%; Hemoglobin \<100 g/L; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3× upper limit of normal range (ULN), total bilirubin (TBIL) ≥2.0×ULN; Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2 (calculated based on serum creatinine using CKD-EPI formula); Fasting triglyceride (TG) \>5.64 mmol/L (500 mg/dl); calcitonin ≥50 ng/L; Blood amylase or lipase ≥3×ULN; Thyroid stimulating hormone (TSH) \<0.4 or \>6.0 mIU/L; Abnormalities in other laboratory tests that the investigator determines may affect the assessment of efficacy or safety;
• 、The 12-lead electrocardiogram (ECG) examination revealed clinically significant abnormalities that the investigators determined may affect the safety of the subject and QTcF\>450 ms; 11、Poor blood pressure control: systolic blood pressure ≥160 mmHg, or diastolic blood pressure ≥110 mmHg, or diastolic blood pressure ≥100mmHg and deemed unsuitable for study by investigator; 12、Clinically relevant medical behavior or psychiatric disorder (other than OSA), that is associated with insomnia or excessive sleepiness in the past and at the time of screening; 13、Severe infection, severe trauma, or major or large surgery within 1 month prior to screening 14、Malignancy of any organ system within 5 years, regardless of evidence of local recurrence or metastasis; 15、A known or suspected history of alcohol and/or drug abuse; 16、The presence of a serious hematological disorder; 17、Surgery is planned during the trial (except for minor surgery that the investigators believe will not affect the trial) 18、Mentally incapacitated or speech-impaired subjects are unable to fully understand or participate in the test process; 19、In the investigator's judgment, there are circumstances (medical, psychological, social, or geographical factors, etc.) that affect subject safety or any other conditions that interfere with the evaluation of test results.

Sponsors & Collaborators

• Fujian Shengdi Pharmaceutical Co., Ltd.: lead

Central Study Contacts

Shuang Li

CONTACT

0518-82342973; Shuang.li.sl100@hengrui.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 20, 2024
• First Posted: August 22, 2024
• Study Start: August 1, 2024
• Primary Completion: December 1, 2025
• Study Completion: December 1, 2025
• Last Updated: August 22, 2024

Record last verified: 2024-08